Based on this review, it was determined that the HPV vaccine is associated with a higher frequency of local or systemic adverse events such as pain OR = 3.29; 95%: 3.00 to 3.60; 6 studies, 9,427 participants. I2: 19 %; erythema OR = 2.41; 95% CI: 2.17 to 2.68; 5 studies, 9,133 participants. I2: 70 %; oedema OR = 3.14; 95% CI: 2.79 to 3.53; 5 studies, 9,133 participants. I2: 78 %; fever OR = 1.21; 95% CI: 1.03 to 1.42; 4 studies, 8,788 participants. I2: 0 %; fatigue OR = 1.29; 95% CI: 1.18 to 1.42; 5 studies, 9,082 participants. I2: 56 %; headache OR = 1.17; 95% CI: 1.06 to 1.28; 4 studies, 8,788 participants. I2: 61 %; myalgia OR = 1.97; 95% CI: 1.77 to 2.20; 4 studies, 8,013 participants. I2: 57 %; and arthralgia OR = 1.40; 95% CI: 1.20 to 1.64; 3 studies, 7,719 participants.
Con base en esta revisión se pudo establecer que la administración de la vacuna para el VPH se asocia con una mayor frecuencia de eventos adversos locales o sistémicos tales como: dolor OR = 3,29; IC 95 %: 3,00 a 3,60; 6 estudios, 9.427 participantes, I2: 19 %, eritema OR = 2,41; IC 95 %: 2,17 a 2,68; 5 estudios, 9.133 participantes, I2: 70 %, edema OR = 3,14; IC 95 %: 2,79 a 3,53; 5 estudios, 9.133 participantes, I2: 78 %, fiebre OR = 1,21; IC 95 %: 1,03 a 1,42; 4 estudios, 8.788 participantes, I2: 0 %, fatiga OR = 1,29; IC 95 %: 1,18 a 1,42; 5 estudios, 9.082 participantes, I2: 56 %, cefalea OR = 1,17; IC 95 %: 1,06 a 1,28; 4 estudios, 8.788 participantes, I2: 61 %, mialgias OR = 1,97; IC 95 %: 1,77 a 2,20; 4 estudios, 8.013 participantes, I2: 57 % y artralgias OR = 1,40; IC 95 %: 1,20 a 1,64; 3 estudios, 7.719 participantes, I2: 40 %.